» Articles » PMID: 34771717

Active Surveillance in Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia

Abstract

Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyroid cancer (MTC) due to germline mutations of gene. Subjects harboring a germline mutation without any clinical signs of MTC are defined as gene carriers (GCs), for whom guidelines propose a prophylactic thyroid surgery. We evaluate if active surveillance of GCs, pursuing early thyroid surgery, can be safely proposed and if it allows safely delaying thyroid surgery in children until adolescence/adulthood. We prospectively followed 189 GCs with moderate or high risk germline mutation. Surgery was planned in case of: elevated basal calcitonin (bCT) and/or stimulated CT (sCT); surgery preference of subjects (or parents, if subject less than 18 years old); other reasons for thyroid surgery. Accordingly, at screening, we sub-grouped GCs in subjects who promptly were submitted to thyroid surgery (Group A, = 67) and who were not (Group B, = 122). Group B was further sub-grouped in subjects who were submitted to surgery during their active surveillance (Group B1, = 22) and who are still in follow-up (Group B2, = 100). Group A subjects presented significantly more advanced age, bCT and sCT compared to Group B. Mutation was the most common variant in both groups but it was significantly less frequent in Group A than B. Analyzing age, bCT, sCT and genetic landscape, Group B1 subjects differed from Group B2 only for sCT at last evaluation. Group A subjects presented more frequently MTC foci than Group B1. Moreover, Group A MTCs presented more aggressive features (size, T and N) than Group B1. Accordingly, at the end of follow-up, all Group B1 subjects presented clinical remission, while 6 and 12 Group A MTC patients had structural and biochemical persistent disease, respectively. Thank to active surveillance, only 13/63 subjects younger than 18 years at screening have been operated on during childhood and/or adolescence. In Group B1, three patients, while actively surveilled, had the possibility to reach the age of 18 (or older) and two patients the age of 15, before being submitted to thyroid surgery. In Group B2, 12 patients become older than 18 years and 17 older than 15 years. In conclusion, we demonstrated that an active surveillance pursuing an early thyroid surgery could be safely recommended in GCs. This patient-centered approach permits postponing thyroid surgery in children until their adolescence/adulthood. At the same time, we confirmed that genetic screening allows finding hidden MTC cases that otherwise would be diagnosed much later.

Citing Articles

Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.

Martins R, Jesus T, Cardoso L, Soares P, Vinagre J J Pers Med. 2023; 13(7).

PMID: 37511745 PMC: 10381735. DOI: 10.3390/jpm13071132.


Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.

Elisei R, Romei C Endocrine. 2023; 81(2):206-215.

PMID: 37195581 DOI: 10.1007/s12020-023-03368-w.


Endocrine and Neuroendocrine Tumors: A Special Issue.

Berruti A, Amoroso V, Fazio N Cancers (Basel). 2022; 14(20).

PMID: 36291777 PMC: 9599373. DOI: 10.3390/cancers14204994.

References
1.
Tuggle C, Roman S, Wang T, Boudourakis L, Thomas D, Udelsman R . Pediatric endocrine surgery: who is operating on our children?. Surgery. 2008; 144(6):869-77. DOI: 10.1016/j.surg.2008.08.033. View

2.
Modigliani E, Cohen R, Campos J, Conte-Devolx B, Maes B, Boneu A . Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf). 1998; 48(3):265-73. DOI: 10.1046/j.1365-2265.1998.00392.x. View

3.
Russell M, Kamani D, Randolph G . Modern surgery for advanced thyroid cancer: a tailored approach. Gland Surg. 2020; 9(Suppl 2):S105-S119. PMC: 7044078. DOI: 10.21037/gs.2019.12.16. View

4.
Machens A, Lorenz K, Weber F, Dralle H . Genotype-specific progression of hereditary medullary thyroid cancer. Hum Mutat. 2018; 39(6):860-869. DOI: 10.1002/humu.23430. View

5.
Amodru V, Taieb D, Guerin C, Romanet P, Paladino N, Brue T . MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine. 2020; 69(3):496-503. DOI: 10.1007/s12020-020-02332-2. View